Focusing  ||| S:0 E:9 ||| VBG
the  ||| S:9 E:13 ||| DT
HIV  ||| S:13 E:17 ||| NNP
response  ||| S:17 E:26 ||| NN
through  ||| S:26 E:34 ||| IN
estimating  ||| S:34 E:45 ||| VBG
the  ||| S:45 E:49 ||| DT
major  ||| S:49 E:55 ||| JJ
modes  ||| S:55 E:61 ||| NNS
of  ||| S:61 E:64 ||| IN
HIV  ||| S:64 E:68 ||| NNP
transmission ||| S:68 E:80 ||| NN
:  ||| S:80 E:82 ||| :
a  ||| S:82 E:84 ||| DT
multi-country  ||| S:84 E:98 ||| JJ
analysis  ||| S:98 E:107 ||| NN
An  ||| S:107 E:110 ||| DT
increasing  ||| S:110 E:121 ||| JJ
number  ||| S:121 E:128 ||| NN
of  ||| S:128 E:131 ||| IN
countries  ||| S:131 E:141 ||| NNS
have  ||| S:141 E:146 ||| VBP
been  ||| S:146 E:151 ||| VBN
estimating  ||| S:151 E:162 ||| VBG
the  ||| S:162 E:166 ||| DT
distribution  ||| S:166 E:179 ||| NN
of  ||| S:179 E:182 ||| IN
new  ||| S:182 E:186 ||| JJ
adult  ||| S:186 E:192 ||| NN
HIV  ||| S:192 E:196 ||| NN
infections  ||| S:196 E:207 ||| NNS
by  ||| S:207 E:210 ||| IN
modes  ||| S:210 E:216 ||| NNS
of  ||| S:216 E:219 ||| IN
transmission  ||| S:219 E:232 ||| NN
( ||| S:232 E:233 ||| -LRB-
MOT ||| S:233 E:236 ||| NNP
)  ||| S:236 E:238 ||| -RRB-
to  ||| S:238 E:241 ||| TO
help  ||| S:241 E:246 ||| VB
prioritise  ||| S:246 E:257 ||| JJ
prevention  ||| S:257 E:268 ||| NN
efforts ||| S:268 E:275 ||| NNS
.  ||| S:275 E:277 ||| .
We  ||| S:277 E:280 ||| PRP
compare  ||| S:280 E:288 ||| VBP
results  ||| S:288 E:296 ||| NNS
from  ||| S:296 E:301 ||| IN
studies  ||| S:301 E:309 ||| NNS
conducted  ||| S:309 E:319 ||| VBN
between  ||| S:319 E:327 ||| IN
2008  ||| S:327 E:332 ||| CD
and  ||| S:332 E:336 ||| CC
2012  ||| S:336 E:341 ||| CD
and  ||| S:341 E:345 ||| CC
discuss  ||| S:345 E:353 ||| VB
their  ||| S:353 E:359 ||| PRP$
use  ||| S:359 E:363 ||| NN
for  ||| S:363 E:367 ||| IN
planning  ||| S:367 E:376 ||| NN
and  ||| S:376 E:380 ||| CC
responding  ||| S:380 E:391 ||| VBG
to  ||| S:391 E:394 ||| TO
the  ||| S:394 E:398 ||| DT
HIV  ||| S:398 E:402 ||| NNP
epidemic ||| S:402 E:410 ||| NN
.  ||| S:410 E:412 ||| .
The  ||| S:412 E:416 ||| DT
UNAIDS  ||| S:416 E:423 ||| NNP
recommended  ||| S:423 E:435 ||| VBD
MOT  ||| S:435 E:439 ||| NNP
model  ||| S:439 E:445 ||| NN
helps  ||| S:445 E:451 ||| VBZ
countries  ||| S:451 E:461 ||| NNS
to  ||| S:461 E:464 ||| TO
estimate  ||| S:464 E:473 ||| VB
the  ||| S:473 E:477 ||| DT
proportion  ||| S:477 E:488 ||| NN
of  ||| S:488 E:491 ||| IN
new  ||| S:491 E:495 ||| JJ
HIV  ||| S:495 E:499 ||| NN
infections  ||| S:499 E:510 ||| NNS
that  ||| S:510 E:515 ||| WDT
occur  ||| S:515 E:521 ||| VBP
through  ||| S:521 E:529 ||| IN
key  ||| S:529 E:533 ||| JJ
transmission  ||| S:533 E:546 ||| NN
modes  ||| S:546 E:552 ||| NNS
including  ||| S:552 E:562 ||| VBG
sex  ||| S:562 E:566 ||| NN
work ||| S:566 E:570 ||| NN
,  ||| S:570 E:572 ||| ,
injecting  ||| S:572 E:582 ||| VBG
drug  ||| S:582 E:587 ||| NN
use  ||| S:587 E:591 ||| NN
( ||| S:591 E:592 ||| -LRB-
IDU ||| S:592 E:595 ||| NNP
) ||| S:595 E:596 ||| -RRB-
,  ||| S:596 E:598 ||| ,
men  ||| S:598 E:602 ||| NNS
having  ||| S:602 E:609 ||| VBG
sex  ||| S:609 E:613 ||| NN
with  ||| S:613 E:618 ||| IN
men  ||| S:618 E:622 ||| NNS
( ||| S:622 E:623 ||| -LRB-
MSM ||| S:623 E:626 ||| NNP
) ||| S:626 E:627 ||| -RRB-
,  ||| S:627 E:629 ||| ,
multiple  ||| S:629 E:638 ||| JJ
sexual  ||| S:638 E:645 ||| JJ
partnerships ||| S:645 E:657 ||| NNS
,  ||| S:657 E:659 ||| ,
stable  ||| S:659 E:666 ||| JJ
relationships  ||| S:666 E:680 ||| NNS
and  ||| S:680 E:684 ||| CC
medical  ||| S:684 E:692 ||| JJ
interventions ||| S:692 E:705 ||| NNS
.  ||| S:705 E:707 ||| .
The  ||| S:707 E:711 ||| DT
model  ||| S:711 E:717 ||| NN
typically  ||| S:717 E:727 ||| RB
forms  ||| S:727 E:733 ||| JJ
part  ||| S:733 E:738 ||| NN
of  ||| S:738 E:741 ||| IN
a  ||| S:741 E:743 ||| DT
country-led  ||| S:743 E:755 ||| JJ
process  ||| S:755 E:763 ||| NN
that  ||| S:763 E:768 ||| WDT
includes  ||| S:768 E:777 ||| VBZ
a  ||| S:777 E:779 ||| DT
comprehensive  ||| S:779 E:793 ||| JJ
review  ||| S:793 E:800 ||| NN
of  ||| S:800 E:803 ||| IN
epidemiological  ||| S:803 E:819 ||| JJ
data ||| S:819 E:823 ||| NNS
.  ||| S:823 E:825 ||| .
Recent  ||| S:825 E:832 ||| JJ
revisions  ||| S:832 E:842 ||| NNS
to  ||| S:842 E:845 ||| TO
the  ||| S:845 E:849 ||| DT
model  ||| S:849 E:855 ||| NN
are  ||| S:855 E:859 ||| VBP
described ||| S:859 E:868 ||| VBN
.  ||| S:868 E:870 ||| .
Modelling  ||| S:870 E:880 ||| JJ
results  ||| S:880 E:888 ||| NNS
from  ||| S:888 E:893 ||| IN
25  ||| S:893 E:896 ||| CD
countries  ||| S:896 E:906 ||| NNS
show  ||| S:906 E:911 ||| VBP
large  ||| S:911 E:917 ||| JJ
variation  ||| S:917 E:927 ||| NN
between  ||| S:927 E:935 ||| IN
and  ||| S:935 E:939 ||| CC
within  ||| S:939 E:946 ||| IN
regions ||| S:946 E:953 ||| NNS
.  ||| S:953 E:955 ||| .
In  ||| S:955 E:958 ||| IN
sub-Saharan  ||| S:958 E:970 ||| NNP
Africa ||| S:970 E:976 ||| NNP
,  ||| S:976 E:978 ||| ,
new  ||| S:978 E:982 ||| JJ
infections  ||| S:982 E:993 ||| NNS
occur  ||| S:993 E:999 ||| VBP
largely  ||| S:999 E:1007 ||| RB
in  ||| S:1007 E:1010 ||| IN
the  ||| S:1010 E:1014 ||| DT
general  ||| S:1014 E:1022 ||| JJ
heterosexual  ||| S:1022 E:1035 ||| JJ
population  ||| S:1035 E:1046 ||| NN
because  ||| S:1046 E:1054 ||| IN
of  ||| S:1054 E:1057 ||| IN
multiple  ||| S:1057 E:1066 ||| JJ
partnerships  ||| S:1066 E:1079 ||| NNS
or  ||| S:1079 E:1082 ||| CC
in  ||| S:1082 E:1085 ||| IN
stable  ||| S:1085 E:1092 ||| JJ
discordant  ||| S:1092 E:1103 ||| JJ
relationships ||| S:1103 E:1116 ||| NNS
,  ||| S:1116 E:1118 ||| ,
while  ||| S:1118 E:1124 ||| IN
sex  ||| S:1124 E:1128 ||| NN
work  ||| S:1128 E:1133 ||| NN
contributes  ||| S:1133 E:1145 ||| VBZ
significantly  ||| S:1145 E:1159 ||| RB
to  ||| S:1159 E:1162 ||| TO
new  ||| S:1162 E:1166 ||| JJ
infections  ||| S:1166 E:1177 ||| NNS
in  ||| S:1177 E:1180 ||| IN
West  ||| S:1180 E:1185 ||| NNP
Africa ||| S:1185 E:1191 ||| NNP
.  ||| S:1191 E:1193 ||| .
IDU  ||| S:1193 E:1197 ||| NNP
and  ||| S:1197 E:1201 ||| CC
sex  ||| S:1201 E:1205 ||| NN
work  ||| S:1205 E:1210 ||| NN
are  ||| S:1210 E:1214 ||| VBP
the  ||| S:1214 E:1218 ||| DT
main  ||| S:1218 E:1223 ||| JJ
contributors  ||| S:1223 E:1236 ||| NNS
to  ||| S:1236 E:1239 ||| TO
new  ||| S:1239 E:1243 ||| JJ
infections  ||| S:1243 E:1254 ||| NNS
in  ||| S:1254 E:1257 ||| IN
the  ||| S:1257 E:1261 ||| DT
Middle  ||| S:1261 E:1268 ||| NNP
East  ||| S:1268 E:1273 ||| NNP
and  ||| S:1273 E:1277 ||| CC
North  ||| S:1277 E:1283 ||| NNP
Africa ||| S:1283 E:1289 ||| NNP
,  ||| S:1289 E:1291 ||| ,
with  ||| S:1291 E:1296 ||| IN
MSM  ||| S:1296 E:1300 ||| NNP
the  ||| S:1300 E:1304 ||| DT
main  ||| S:1304 E:1309 ||| JJ
contributor  ||| S:1309 E:1321 ||| NN
in  ||| S:1321 E:1324 ||| IN
Latin  ||| S:1324 E:1330 ||| NNP
America ||| S:1330 E:1337 ||| NNP
.  ||| S:1337 E:1339 ||| .
Patterns  ||| S:1339 E:1348 ||| NNS
vary  ||| S:1348 E:1353 ||| VBP
substantially  ||| S:1353 E:1367 ||| RB
between  ||| S:1367 E:1375 ||| IN
countries  ||| S:1375 E:1385 ||| NNS
in  ||| S:1385 E:1388 ||| IN
Eastern  ||| S:1388 E:1396 ||| NNP
Europe  ||| S:1396 E:1403 ||| NNP
and  ||| S:1403 E:1407 ||| CC
Asia  ||| S:1407 E:1412 ||| NNP
in  ||| S:1412 E:1415 ||| IN
terms  ||| S:1415 E:1421 ||| NNS
of  ||| S:1421 E:1424 ||| IN
the  ||| S:1424 E:1428 ||| DT
relative  ||| S:1428 E:1437 ||| JJ
contribution  ||| S:1437 E:1450 ||| NN
of  ||| S:1450 E:1453 ||| IN
sex  ||| S:1453 E:1457 ||| NN
work ||| S:1457 E:1461 ||| NN
,  ||| S:1461 E:1463 ||| ,
MSM ||| S:1463 E:1466 ||| NNP
,  ||| S:1466 E:1468 ||| ,
IDU  ||| S:1468 E:1472 ||| NNP
and  ||| S:1472 E:1476 ||| CC
spousal  ||| S:1476 E:1484 ||| JJ
transmission ||| S:1484 E:1496 ||| NN
.  ||| S:1496 E:1498 ||| .
The  ||| S:1498 E:1502 ||| DT
MOT  ||| S:1502 E:1506 ||| NNP
modelling  ||| S:1506 E:1516 ||| NN
results ||| S:1516 E:1523 ||| NNS
,  ||| S:1523 E:1525 ||| ,
comprehensive  ||| S:1525 E:1539 ||| JJ
review  ||| S:1539 E:1546 ||| NN
and  ||| S:1546 E:1550 ||| CC
critical  ||| S:1550 E:1559 ||| JJ
assessment  ||| S:1559 E:1570 ||| NN
of  ||| S:1570 E:1573 ||| IN
data  ||| S:1573 E:1578 ||| NNS
in  ||| S:1578 E:1581 ||| IN
a  ||| S:1581 E:1583 ||| DT
country  ||| S:1583 E:1591 ||| NN
can  ||| S:1591 E:1595 ||| MD
contribute  ||| S:1595 E:1606 ||| VB
to  ||| S:1606 E:1609 ||| TO
a  ||| S:1609 E:1611 ||| DT
more  ||| S:1611 E:1616 ||| RBR
strategically  ||| S:1616 E:1630 ||| RB
focused  ||| S:1630 E:1638 ||| VBN
HIV  ||| S:1638 E:1642 ||| NNP
response ||| S:1642 E:1650 ||| NN
.  ||| S:1650 E:1652 ||| .
To  ||| S:1652 E:1655 ||| TO
strengthen  ||| S:1655 E:1666 ||| VB
this  ||| S:1666 E:1671 ||| DT
type  ||| S:1671 E:1676 ||| NN
of  ||| S:1676 E:1679 ||| IN
research ||| S:1679 E:1687 ||| NN
,  ||| S:1687 E:1689 ||| ,
improved  ||| S:1689 E:1698 ||| JJ
epidemiological  ||| S:1698 E:1714 ||| NN
and  ||| S:1714 E:1718 ||| CC
behavioural  ||| S:1718 E:1730 ||| JJ
data  ||| S:1730 E:1735 ||| NNS
by  ||| S:1735 E:1738 ||| IN
risk  ||| S:1738 E:1743 ||| NN
population  ||| S:1743 E:1754 ||| NN
are  ||| S:1754 E:1758 ||| VBP
needed ||| S:1758 E:1764 ||| VBN
.  ||| S:1764 E:1766 ||| .
